Conference Buzz
Top Themes at ESMO Breast 2026
Most-discussed scientific topics across 48 curated tweets from 23 researchers and oncologists. Tap any card to see the tweets.
13
Early Breast Cancer
14.5K impressions
tap to see tweets
7
Endocrine / SERD / CDK
1.0K impressions
tap to see tweets
6
HER2-Directed Therapy
11.0K impressions
tap to see tweets
4
Immunotherapy
13.5K impressions
tap to see tweets
3
Triple-Negative BC
12.3K impressions
tap to see tweets
3
Biomarker / Genomics
177 impressions
tap to see tweets
2
ADC / Payload
12.8K impressions
tap to see tweets
2
ctDNA & Liquid Biopsy
7.3K impressions
tap to see tweets
2
Real-World Evidence
458 impressions
tap to see tweets
1
AI in Oncology
195 impressions
tap to see tweets
1
QoL / PROs
257 impressions
tap to see tweets
Leaderboard
Top Voices by Impressions
Ranked by total impressions across all ESMO Breast 2026 tweets captured. Switch tabs to view physicians, institutions, and media separately.
Top Tweets & Trials
Top Tweets & Clinical Trials
Highest-impact physician tweets and trial-level discussion. Expand the Clinical Trials section to drill into specific trial buzz.
Breast Cancer48 tweets captured
It’s that time of the year again! #ESMOBreast26 is only a few days away, and promises to bring new important data in breast oncology. This year’s key themes: tailoring therapy for HER2+ eBC, prospective data with ADC sequencing, use of MRD to guide treatment. See you in Berlin! https://t.co/nHzDTWzTlO
👁 7.1K
❤ 142
🔁 50
🔥 ADC + Immunotherapy in TNBC?
#ESMOBreast26
Early data from 426RO trial shows a striking signal in 1L mTNBC 👇
🧪 Trial: Phase I/II (n=30)
👥 Population: 1L advanced/metastatic TNBC
💊 Regimen
👉 Pumitamig (PD-L1 × VEGF-A bispecific)
➕
👉 DB-1305/BNT325 (TROP2 ADC)
🎯 https://t.co/cauJOBGn8w https://t.co/hwB5ljn3wY
👁 5.7K
❤ 32
🔁 19
Such an important study showing no benefit to adjuvant Atezolizumab added to capecitabine in TNBC patients with residual disease. More to come at #ESMOBreast 2026 https://t.co/2GheZWrC8J
👁 4.3K
❤ 32
🔁 12
Actually the trial was not powered at all for OS. Wait for the data. This was a secondary endpoint and the assumptions were not attainable. Pragmatic decisions. @oncoalert. @myESMO #esmobc26 https://t.co/CCo59FIfT7
👁 3.5K
❤ 33
🔁 4
#ESMOBreast26 starts tomorrow.
Ready and in place for the updates.
@myESMO https://t.co/6WH2y2UYhn https://t.co/znCS0SsZ5B
👁 1.1K
❤ 12
🔁 3
Esmo Breast 2026 - LBAs are out . What's the new data from Destiny Breast 11 ?
It improves RCB across all the subgroups. Looking forward to full data. @myESMO #esmobreast26 https://t.co/6t1iXeQmDi
👁 974
❤ 20
🔁 9
Clinical Trials7 trials with discussion
SACI-IO HR+
Sacituzumab Govitecan + Pembro · HR+/HER2- MBC
▼
DESTINY-Breast11
T-DXd → THP · High-Risk HER2+ Stage II-III eBC
▼
TRAIN-4
Trastuzumab + Pertuzumab + Tucatinib · Chemo-Free Neoadj HER2+ eBC
▼
🔬 Chemo-free HER2+ breast cancer treatment is no longer just a concept.
TRAIN-4 trial — Trastuzumab + Pertuzumab + Tucatinib triple HER2 blockade.
Excellent efficacy without chemo toxicity → this could redefine neoadjuvant standards.
#EsmoBreast2026 #BreastCancer #Oncology https://t.co/raCAtvTubU
👁 257
❤ 1
🔁 0
@DrRishabhOnco Actually, TRAIN-4 is testing a fully chemotherapy-free triple HER2 blockade:
Trastuzumab + Pertuzumab + Tucatinib (no T-DM1).
It showed impressive results:
→ 93% major shrinkage after 3 cycles
→ 73% pCR
Great proof-of-concept for no chemo approach!
#ESMOBreast2026 #MVOnco
👁 220
❤ 3
🔁 0
TRAK-ER
ctDNA Surveillance · High-Risk HR+/HER2- eBC
▼
PHERGain-2
Neoadjuvant HP-only · Small Node-Negative HER2+ eBC
▼
PHERGain
Personalized HER2+ eBC · PET-Adapted Therapy
▼
CAPItello-291
Capivasertib + Fulvestrant · HR+/HER2- MBC (Final OS)
▼
News & Publications
Major Media Coverage at ESMO Breast 2026
Key stories, publications, and press coverage from the ESMO Breast Cancer Annual Congress — curated from major oncology media.
Publication
DESTINY-Breast11: T-DXd → THP Achieves 67.3% pCR vs 56.3% Standard of Care in High-Risk HER2+ eBC
Phase 3 trial in 927 patients: T-DXd followed by paclitaxel + trastuzumab + pertuzumab significantly outperformed ddAC-THP in pCR (67.3% vs 56.3%, +11.2 points, p=0.003) with markedly lower grade ≥3 AEs (37.5% vs 55.8%) and reduced LV dysfunction.
PublicationTROPION-Breast02: Datopotamab Deruxtecan Doubles PFS vs Chemo in 1L mTNBC
Phase 3 trial in 644 patients with previously untreated mTNBC ineligible for IO: Dato-DXd improved mPFS to 10.8 vs 5.6 months (HR 0.57, p<0.0001) with comparable grade ≥3 AEs and lower discontinuation (4% vs 7%).
PublicationSERENA-6: Camizestrant Switch on ESR1m Detection Improves PFS and Quality of Life
ctDNA-guided switch from AI to camizestrant + CDK4/6i at ESR1m emergence delayed deterioration in global health (HR 0.54), pain (HR 0.57), fatigue (HR 0.75), and physical functioning (HR 0.74) vs continued AI + CDK4/6i.
FDAFDA ODAC Reviews Camizestrant SERENA-6 Benefit-Risk — Outcome Pending
Oncologic Drugs Advisory Committee discussed whether SERENA-6 demonstrates favorable benefit-risk for camizestrant + CDK4/6i in HR+/HER2- MBC at ESR1m detection. FDA noted overall positive benefit-risk remains uncertain.
Press ReleaseFDA Accepts NDA for Giredestrant + Everolimus in ESR1m HR+/HER2- MBC — PDUFA Dec 18, 2026
Filing based on Phase 3 evERA: giredestrant + everolimus reduced risk of progression or death by 44% ITT and 62% in ESR1m population vs SOC endocrine + everolimus. Could become first oral SERD combo approved post-CDK4/6i.
Press ReleaseGiredestrant Becomes First Oral SERD to Show Adjuvant Benefit — lidERA Phase 3
Giredestrant reduced risk of invasive disease recurrence or death by 30% (HR 0.70, p=0.0014) vs SOC endocrine therapy in ER+/HER2- early breast cancer at pre-specified interim analysis — first major endocrine advance in 20+ years.
Media CoverageESMO Breast 2026 Preview: Less Chemo, Smarter Targeting, More Personalization
Olubukola Ayodele (Leicester) frames the conference's three central themes: chemotherapy de-escalation in HER2+ disease (DESTINY-Breast11, PHERGain-2, TRAIN-4), ADC dominance across subtypes, and biomarker-driven sequencing.
Media CoverageTop Trials to Watch at ESMO Breast 2026 — Rishabh Jain Pre-Conference Analysis
Comprehensive preview of TROPION-Breast02, DESTINY-Breast11, SATEEN, HER2CLIMB-02, PREcoopERA, PERSEVERE, MIRINAE, SACI-IO HR+, and other key abstracts shaping breast oncology practice.
Media CoveragectDNA Surveillance for MRD Detection — Already Changing Management in 80%+ of Positive Cases
Marla Lipsyc-Sharf (UCLA): real-world Signatera data from 7,984 adjuvant breast cancer patients shows positive ctDNA changes management in >80% of cases, with median 13.3 months lead time before radiographic recurrence.
Press ReleaseINAVO120: Inavolisib + Palbo + Fulvestrant Prolongs OS in PIK3CA-Mutated HR+/HER2- MBC
Phase 3 final OS analysis confirms inavolisib triplet improves overall survival in 1L PIK3CA-mutated, endocrine-resistant advanced breast cancer — establishing new standard for this molecularly defined subset.
FDAFDA Approves T-DXd + Pertuzumab for 1L HER2+ Metastatic Breast Cancer (DESTINY-Breast09)
Approval reshapes the HER2+ MBC treatment landscape just months before ESMO Breast 2026 — T-DXd + pertuzumab becomes the new 1L standard, raising sequencing questions for HER2CLIMB-02 and other 2L+ regimens.
Media CoverageWhat to Look Out For at ESMO Breast Cancer 2026
Pre-conference roundup of key abstracts and emerging treatment paradigms across HER2+, HR+, and TNBC — including ADC sequencing, oral SERDs, and ctDNA-guided precision adjuvant therapy.